NCT04042701: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that are either HER2+ (IHC 3+ or HER2-low defined as IHC 1+ or 2+ & ISH-negative)
Exclusions: Patients with prior treatment of DS-8201a/Enhertu and pembrolizumab/Keytruda or any anti-PD-1/L1 antibody; Patients with clinically active central nervous system metastases

Comments are closed.

Up ↑